- Home
- FMY vs MREO Comparison
FMY vs MREO Comparison
Compare FMY & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMY | MREO |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 52.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | FMY | MREO |
|---|---|---|
| Price | $11.61 | $0.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 3.5K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.40 | $0.20 |
| 52 Week High | $12.39 | $2.94 |
Technical Indicators
Market Signals| Indicator | FMY | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 65.86 |
| Support Level | $11.41 | $0.33 |
| Resistance Level | $12.29 | $0.36 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 84.86 | 85.82 |
Price Performance
Historical ComparisonAbout FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).